Long-term effect of nintedanib treatment in 11 countries of Europe and Asia
M. Koziar Vasakova (Prague, Czech Republic), M. Sterclova (Prague, Czech Republic), N. Mogulkoc Bishop (Izmir, Turkey), K. Lewandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Kramer (Petah Tikva, Israel), M. Hajkova (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), M. Studnicka (Salzburg, Austria), J. Tekavec-Trkanjec (Zagreb, Croatia), A. Penev (Sofia, Bulgaria), P. Ovesna (Brno, Czech Republic), J. Gregor (Brno, Czech Republic)
Source: International Congress 2022 – How to prevent progression in idiopathic interstitial pneumonias
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Koziar Vasakova (Prague, Czech Republic), M. Sterclova (Prague, Czech Republic), N. Mogulkoc Bishop (Izmir, Turkey), K. Lewandowska (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Kramer (Petah Tikva, Israel), M. Hajkova (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), M. Studnicka (Salzburg, Austria), J. Tekavec-Trkanjec (Zagreb, Croatia), A. Penev (Sofia, Bulgaria), P. Ovesna (Brno, Czech Republic), J. Gregor (Brno, Czech Republic). Long-term effect of nintedanib treatment in 11 countries of Europe and Asia. 2661
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|